COVID-19
COVID-19, a viral infection, causes increased oxidative stress. These highly reactive free radicals produced from oxidative stress are powerful oxidizing agents due to unpaired electrons in their outer valence orbitals. A breath test for oxidative stress biomarkers (VOC’s such as alkanes and alkane derivatives) could be the basis for a new tool for early diagnosis.
A highly sensitive, specific, non-invasive and cost-effective test using VOCs analysis as a result of oxidative stress offers a potentially powerful new approach to early diagnosis COVID-19. Working with world-renown research institutes and key opinion leaders, Canary’s Airostotle™ platform can be tuned to start immediately - testing in COVID-19 infected patients.
Our goal is to develop a test that can produce a result in less than 5 minutes in infected individuals even before the onset of symptoms. The results will be analyzed in the cloud and the data captured will enable real-time surveillance.
AiroStotle Detect
Airostotle Detect is a diagnostic platform designed and developed to execute tests that enable clinicians to detect diseases and recurrences at stages when intervention has a higher chance to treat. It will also enable the identification of new opportunities in adjuvant drug development and therapies targeting earlier stage diseases and cancers. Canary’s patent pending biomarker sensor technology is capable of predicting the risk of developing cancers, identifying presence of diseases, characterizing the nature and location of cancers, and predicting and monitoring responses to therapy.
AiroStotleLC has the ability to improve stage-at-diagnosis rates by enabling physicians and primary care providers to detect and diagnose cancers at much earlier stages, improving recovery and life expectancy rates and saving lives.
AirostotleLC is being designed and developed to execute tests that enable clinicians to detect disease and recurrence at a stage when intervention may have a higher chance to cure compared to other technologies. It is also designed to help bio-pharmaceutical customers identify new opportunities in adjuvant drug development and therapies targeting earlier stage cancers.
Canary Health Technologies’ AiroStotleLC ABX1 Sensor
AiroStotleLC ABX1 Sensor
real-time breath-based lung cancer detection
Up to 40% of cancerous tumours don’t shed their genetic fragments into the bloodstream, confounding many genetic blood based modalities (liquid biopsies) and limiting them to later stages of cancer detection.
The AiroStotleLC ABX1 sensor is designed to overcome a variety of challenges that have confounded prior approaches to breath-based analysis and early-stage cancer and disease detection. The AiroStotleLC ABX1 can detect digital breath signatures’ bio-patterns of diseases such as lung cancer with high clinical sensitivity and specificity*.
Once the patient blows into the device, breath data (unique VOC patterns) are captured and encoded by our nano-sensors. The breath data is encrypted and communicated to the cloud where it is analyzed and processed in real-time against a VOC pattern recognition database. Results are shared through an integrated application with the physician and patient in near-real-time.
*based on a lab and bench testing and human verification trials
Based on combination of human verification trials, lab tests and bench results.
Airostotle vs Other Diagnostic Technology
AiroStotle sensors are non-invasive, low cost, mobile and able to be used by patients at point-of-care, and provide real-time verification and results to physicians and healthcare providers.
-
Consistent reproducibility between devices
-
No operator or special skillsets are required for use
-
No exposure to radiation or other harmful or invasive chemicals or substances
-
No pre-processing or transportation of samples required.
The AiroStotle Detect Platform
The AiroStotle Detect platform is designed to detect cancers at earlier stages than leading liquid/blood based biopsy detection and/or screening technologies.
Not only can the AiroStotle platform detect earlier stage diseases but it can do so in near-real-time and at the point of care.
Using human breath to detect diseases is a proven science
The area of modern breath testing started in 1971, when Nobel Prize winner Linus Pauling demonstrated that human breath is a complex gas, containing more than 200 different VOCs[1]. Since then, it was discovered that the Human exhaled breath is a complex mixture containing over 3,000 volatile organic compounds (VOCs)[2]. Over the past 47 years breath science has developed significantly to include studies into breath markers for cancers (inter alia lung, breast, colon), infectious diseases, neuro-degenerative diseases and inflammatory disease. We now know that advanced exhaled breath testing can be used to detect and quantify organic compounds VOCs which is correlated to diseases.
Breath testing is currently used by world renown medical centers such as Cleveland Clinic and Mayo Clinic as an increasingly important non-invasive diagnostic method and safer alternative for diagnosing or screening patients for many diseases, including carbohydrate intolerance, Helicobacter pylori infection[3], small bowel bacterial overgrowth, and liver dysfunction. Next generation breath sensor technology such as Airostotle by Canary has the capability to expand the analysis of exhaled breath to complex diseases such lung cancer and other solid tumors. The analysis of exhaled air can be a powerful risk-free intervention for bedside and community-based screening and diagnostics.
[1] Pauling, L.; Robinson, A. B.; Teranishi, R.; Cary, P. (1971-10-01). "Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatograph
[2] Variation in volatile organic compounds in the breath of normal humans. Journal of Chromatography B: Biomedical Sciences and Applications Volume 729, Issues 1–2, 11 June 1999, Pages 75-88 Phillips et al
[3] https://my.clevelandclinic.org/health/diagnostics/5217-helicobacter-pylori-breath-test
More than 80% of lung cancer patients will survive for at least a year if diagnosed at the earliest stage compared to only 15% for people diagnosed with the most advanced stage of disease.
https://www.cancerresearchuk.org/about-cancer/cancer-symptoms/why-is-early-diagnosis-important